Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients

Table 1

Depiction of the clinical characteristics of 20 WED and 29 NED melanoma patients used in this study.

Total number of patients	49 (100%)
Age (years) at treatment		Sex, Female	25 (51%)
<40	9 (18.4%)
41–60	16 (32.7%)
>61	24 (49%)
Stage at presentation		Time from first treatment to last follow up date
Stage II	2	0–12 months	12 (24.5%)
Stage III	32	13–24 months	13 (26.5%)
Stage IV	15	25–36 months	4 (8.2%)
		>37 months	20 (40.8%)
Stage at treatment of NED patients (𝑁=29)		Stage at treatment of WED patients (𝑁=20)
Stage II	2 (6.9%)	Stage III (unresectable)	10 (50%)
Stage III (respectable)	22 (76%)	Stage IV: M1a	1 (5%)
Stage IV: M1b	2 (6.9%)	M1b	1 (5%)
M1c	3 (10.3%)	M1c	8 (40%)
LDH values of NED patients		LDH values of WED patients
Time point 0:		Time point 0:
normal	87% (20/23)	normal	78% (11/14)
above normal	13% (3/23)	above normal	21% (3/14)
Time point 1:		Time point 1:
normal	78% (18/23)	normal	64% (7/11)
above normal	22% (5/23)	above normal	36% (4/11)